Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Next Previous
X
Search
Trial Profile

Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ONCOVIRAC

    • Most Recent Events

    • 26 Oct 2017 Status changed from not yet recruiting to recruiting, according to a Transgene media release.
    • 26 Oct 2017 According to a Transgene media release, Dr. Ahmed Idbaih from La Pitie-Salpetriere hospital is the principal investigator, and first readouts of the study are expected in the second half of 2018.
    • 26 Oct 2017 According to a Transgene media release, first patient has been treated at La Pitie-Salpetriere hospital, Greater Paris University Hospitals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top